227 related articles for article (PubMed ID: 26582320)
21. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
22. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
23. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
[TBL] [Abstract][Full Text] [Related]
24. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
26. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
27. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
[TBL] [Abstract][Full Text] [Related]
30. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
[TBL] [Abstract][Full Text] [Related]
31. Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
Kunnimalaiyaan S; Sokolowski K; Gamblin TC; Kunnimalaiyaan M
Am J Surg; 2017 Apr; 213(4):645-651. PubMed ID: 28007318
[TBL] [Abstract][Full Text] [Related]
32. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
33. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
34. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
35. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
36. Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p.
You BR; Park WH
Mol Carcinog; 2017 Dec; 56(12):2566-2577. PubMed ID: 28667779
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
38. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
39. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
